Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)

NCT06934538 is registered in ClinicalTrials.gov with Brenus Pharma as lead sponsor.

NCT NCT06934538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06934538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)
Lead sponsor
Brenus Pharma
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 17, 2025
Completion date
June 30, 2029
Enrollment
90 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable locally advanced colorectal cancer, unresectable metastatic colorectal cancer